PCSK9 Predicts Adverse Limb Outcomes After Endovascular Revascularization in Diabetic Chronic Limb-threatening Ischemia
Thrombosis and Haemostasis · 01.08.2026 · 126 (08) · 846-855
DOI: 10.1055/a-2717-3194 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.08.2026. Verfasst von Federico Biscetti und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Internal Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy. Hauptthemen laut MEDLINE: Proprotein Convertase 9, Diabetes Mellitus, Type 2, Ischemia, Peripheral Arterial Disease. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Proprotein convertase subtilisin/kexin type-9 (PCSK9) plays a crucial role in pathophysiologic processes leading to limb and cardiovascular complications in diabetes, including cholesterol homeostasis, inflammation, and endothelial oxidative stress. This study examined the association between PCSK9 levels and major adverse limb events (MALEs) in patients with type 2 diabetes mellitus (T2DM) and chronic limb-threatening ischemia (CLTI) after endovascular revascularization. This prospective cohort study included 147 T2DM patients with peripheral artery disease undergoing endovascular revascularization for CLTI. Clinical assessments, including PCSK9 blood levels, were performed, and patients were followed for 12 months to monitor MALEs. Logistic regression and ROC curve analyses assessed the relationship between PCSK9 and MALEs. During follow-up, 53 patients experienced MALEs. These patients were younger and had more severe peripheral artery disease. PCSK9 levels were significantly higher in those with MALEs (410.5 ng/mL) versus those without (360.6 ng/mL). ROC analysis showed that adding PCSK9 to cardiovascular risk factors improved MALE prediction. PCSK9 levels and Rutherford 4 category were independent risk factors for MALEs. Elevated PCSK9 levels are strongly associated with increased MALE risk in T2DM patients and may influence age of presentation and disease severity in CLTI. These findings highlight PCSK9 as a potential predictive biomarker and therapeutic target for vascular complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cardiovascular Internal Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
- Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Roma, Italy.
- Radiology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy.
- Division of Vascular and Endovascular Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, United States.
- Diabetology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy.
- Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
ORCID-Profile: Federico Biscetti
Zitieren
APA
Biscetti, F., Rando, M. M., Nicolazzi, M. A., Polito, G., Pecorini, G., Angelini, F., Iezzi, R., Eraso, L. H., Dimuzio, P. J., Pitocco, D., Massetti, M., Gasbarrini, A., & Flex, A. (2026). PCSK9 Predicts Adverse Limb Outcomes After Endovascular Revascularization in Diabetic Chronic Limb-threatening Ischemia. Thrombosis and Haemostasis, 126(08), 846-855. https://doi.org/10.1055/a-2717-3194
Vancouver
Biscetti F, Rando MM, Nicolazzi MA, Polito G, Pecorini G, Angelini F, et al. PCSK9 Predicts Adverse Limb Outcomes After Endovascular Revascularization in Diabetic Chronic Limb-threatening Ischemia. Thrombosis and Haemostasis. 2026;126(08):846-855. doi:10.1055/a-2717-3194
BibTeX
@article{Biscetti2026,
author = {Biscetti, Federico and Rando, Maria Margherita and Nicolazzi, Maria Anna and Polito, Giorgia and Pecorini, Giovanni and Angelini, Flavia and Iezzi, Roberto and Eraso, Luis H and Dimuzio, Paul J and Pitocco, Dario and Massetti, Massimo and Gasbarrini, Antonio and Flex, Andrea},
title = {PCSK9 Predicts Adverse Limb Outcomes After Endovascular Revascularization in Diabetic Chronic Limb-threatening Ischemia},
journal = {Thrombosis and Haemostasis},
year = {2026},
volume = {126},
number = {08},
pages = {846--855},
doi = {10.1055/a-2717-3194}
}
EUVIMED